Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma

Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma. BEZ235 is an effective dual PI3K/mTOR inhibitor, but it was withdrawn from early-phase clinical trials owing to poor solubility and on-target/off-tumor toxicity. Here, we developed a nanoparticle (NP)–based pret...

Descripción completa

Detalles Bibliográficos
Autores principales: Au, Kin Man, Wang, Andrew Z., Park, Steven I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112753/
https://www.ncbi.nlm.nih.gov/pubmed/32270047
http://dx.doi.org/10.1126/sciadv.aaz9798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112753/
https://www.ncbi.nlm.nih.gov/pubmed/32270047
http://dx.doi.org/10.1126/sciadv.aaz9798

Ejemplares similares